Annex Publishers | www.annexpublishers.com Research Article Open Access Volume 3 | Issue 2 Introduction Efect of Levonorgestrel-Releasing Intrauterine System on Sexual and Urinary Functions Arlıer S * , Uysal G, Seyfettinoğlu S, Nazik H, Kaya FO, Adıgüzel C, Yılmaz ES and Yücel O Adana Numune Training and Research Hospital, Department of Obstetrics and Gynecology, Adana, Turkey * Corresponding author: Arlıer S, Adana Numune Training and Research Hospital, Department of Obstetrics and Gynecology, Adana, Turkey, Fax: +90 (322) 344 15 72, Tel: 905324861668, E-mail: sefaarlier@gmail.com Citation: Arlıer S, Uysal G, Seyfettinoğlu S, Nazik H, Kaya FO, et al. (2017) Efect of Levonorgestrel-Releas- ing Intrauterine System on Sexual and Urinary Functions. J Gynecol Res 3(2): 202 Aim: Te efects of the levonorgestrel-intrauterine system (LNG-IUS) on urinary and sexual functions of women with idiopathic menorrhagia were evaluated using two internationally validated questionnaire forms. Abstract Keywords: Levonorgestrel-Releasing Intrauterine System; Menorrhagia; Urinary Function; Sexual Function Volume 3 | Issue 2 Journal of Gynecology Research ISSN: 2454-3284 Menorrhagia and chronic pelvic pain negatively afect the quality of life as well as sexual and urinary functions of women [4-9]. In cases of unresponsiveness to medical treatment, radical elimination of abnormal uterine bleeding by hysterectomy may worsen sexual and urinary functions. In addition to an increased risk of morbidity and mortality, damage to the innervation of the pelvic region may cause further health issues [10]. Te LNG-IUS is an efective, reliable, reversible and relatively less invasive low cost therapy to treat menorrhagia, endometrial hyperplasia, and dysmenorrhea [11]. Te levonorgestrel-intrauterine system (LNG-IUS; Mirena® Leiras Oy, Turku, Finland) has been used worldwide for various clinical indications, such as menorrhagia and dysmenorrhea, in addition to its common use as a contraceptive since it was frst commercially introduced in 1990 [1]. Initially, 20-μg levonorgestrel is released within 24 hours, while levonorgestrel release has been demonstrated to continue in a dose of higher than 14 μg at the end of 5 years [2]. Te efcacy of treatment is continuous by means of this regular release [3]. By evaluating the efects of abnormal uterine bleeding, pelvic pain, and pressure on sexual functions, Mathias et al. [12] established menorrhagia and pelvic organ prolapse [13] as one of the most important underlying factors afecting sexual functions. Similarly, abnormal uterine bleeding was similarly proven to negatively afect the quality of life of women [14,15]. Methods: Tis prospective study included (30-49) year-old women with idiopathic menorrhagia (n=91), who visited the Gynecology and Obstetrics Clinic of the hospital. Te index of female sexual function (IFSF) questionnaire and the international consultation on incontinence modular questionnaire short form (ICIQ-UI) were used to evaluate sexual and urinary system functions, respectively, pre-, and 6 and 12 months post-LNG-IUS insertion. Results: Te IFSF scores were (mean ± SD) 27.1 ± 6.9, 30.0 ± 7.2, and 32.7 ± 7.5 at pre-, and 6 and 12 months post-LNG-IUS insertion, respectively (p<0.001). Compared with pre-LNG-IUS use among 91 patients, the IFSF score (symptoms improved) was increased in 47 and 60 patients and decreased (worsening symptoms) in 10 and 8 patients at 6 and 12 months post-LNG-IUS use, respectively. Te ICIQ-UI scores were 4.9 ± 4.4, 3.7 ± 4.0, 2.8 ± 3.0 in pre-, 6, and 12 months post-LNG-IUS insertion, respectively (p<0.001). Compared with pre-LNG-IUS use, the ICIQ-UI score decreased (symptoms improved) in 33 women either in 6 or 12 months post-LNG-IUS use and increased (symptoms worsened) in 11 and 4 patients at 6 and 12 months post-LNG-IUS insertion, respectively. Conclusion: A signifcant increase in the IFSF score and a marked decrease in the ICIQ-SF score because of LNG-IUS use in women with idiopathic menorrhagia indicate a noteworthy improvement in urinary and sexual functions. Te literature contains a few studies that have evaluated the efect of LNG-IUS use on either urinary or sexual functions in patients with menorrhagia [16-19]. However, this is the frst study to evaluate both urinary functions and sexual life by using two internationally validated standard questionnaires to objectively establish the efects of LNG-IUS use on urinary and sexual functions of women with menorrhagia. Received Date: August 23, 2017 Accepted Date: December 27, 2017 Published Date: December 29, 2017